ESG

How a unique Japanese hospitality philosophy helped Japan House London beat 1,600 rivals to be crowned the best visitor experience in the UK's cultural sector.

A lucrative deal for a rare disease voucher positions Fortress Biotech for profitability, highlighting a successful strategy and a breakthrough for Menkes patients.

With a record 8 million kg of batteries collected in 2025, Canada is winning its fight against waste. See how local efforts are paving the way for an EV future.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

New federal initiatives are fast-tracking deep brain stimulation research, a move championed by Nexalin Technology that could revolutionize care for veterans.

America's power grid is at a breaking point. A new report reveals how homeowners and smart tech are forging a resilient, decentralized energy future.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

Insulation giant PrimaLoft taps a BOA Technology veteran as its new president, signaling a strategic push for commercial growth in the sustainable materials sector.

An international initiative uniting a Japanese firm, the UN, and Aikido masters empowers Los Angeles women with non-violent self-defense techniques.

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

Keurig's ubiquitous K-Cup pods are now recyclable in Ontario, marking a pivotal test for the province's new producer-funded waste system.